Patent intelligence · US
US 12325854
Crispr-CPF1-related methods, compositions and components for cancer immunotherapy
Crispr-CPF1-related methods, compositions and components for cancer immunotherapy
Patent details — US 12325854
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 10, 2025
- Expiration
- Jun 5, 2045
- Applicant
- Editas Medicine, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K35/17, A61P, A61P35/00
Quick answer
US 12325854 (Crispr-CPF1-related methods, compositions and components for cancer immunotherapy) is held by Editas Medicine, Inc.. Status: granted. Granted Jun 10, 2025. Expires Jun 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K35/17, A61P, A61P35/00, A61P35/02
More from Editas Medicine, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12359223
Systems and methods for modulating chromosomal rearrangements
granted -
US 12331328
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
granted -
US 12201699
Compositions and methods for promoting homology directed repair
granted -
US 12031132
Systems and methods for the treatment of hemoglobinopathies
granted -
US 11963982
CRISPR/RNA-guided nuclease systems and methods
granted -
US 11952408
HPV-specific binding molecules
granted -
US 11911415
CRISPR/Cas-related methods and compositions for improving transplantation
granted
Frequently asked questions
What is US patent 12325854?
US 12325854 (Crispr-CPF1-related methods, compositions and components for cancer immunotherapy) is held by Editas Medicine, Inc.. Status: granted. Granted Jun 10, 2025. Expires Jun 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12325854?
Editas Medicine, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 12325854 expire?
Our index shows an expiration date of Jun 5, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.